Filing summary
Identity and period: The request identifies Neurogene Inc., but the supplied filing is Neoleukin Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing.
Business context and reporting period
Neoleukin is a pre-revenue biopharmaceutical company developing de novo protein-based immunotherapies for cancer, inflammation, and autoimmunity. Its lead candidate, NL-201, is designed to mimic IL-2 and IL-15 activity while avoiding binding to the CD25 receptor subunit. The company had no approved products and no product revenue in 2020.
Financial and operating metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $24.3 million | $4.4 million |
| General and administrative expense | $17.2 million | $18.8 million |
| Operating loss | $33.7 million | $71.0 million |
| Net loss | $33.3 million | $69.4 million |
| Net loss per share, basic and diluted | $0.64 | $2.57 |
| Cash and cash equivalents at year-end | $192.6 million | $143.1 million |
| Net cash used in operating activities | $24.6 million | $15.4 million |
| Net cash used in investing activities | $2.2 million | $0.7 million |
| Net cash provided by financing activities | $77.1 million | $82.2 million |
At December 31, 2020, working capital was $186.6 million and total liabilities were $19.3 million, primarily including operating and finance lease liabilities. The filing reports $11.965 million in total lease liabilities; it does not report conventional borrowings. Cash, cash equivalents, and restricted cash totaled $193.4 million, including $0.9 million of restricted cash. Profit margins are not meaningful because the company had no product revenue and reported losses.
Material changes versus 2019
- R&D expense rose by $19.9 million, mainly reflecting NL-201 IND-enabling work and advancement of other platform programs.
- Net loss narrowed by $36.2 million. The comparison is substantially affected by the $47.7 million acquired in-process R&D charge recorded in 2019 in connection with the merger.
- 2020 results included a $7.8 million gain on the sale of Aquinox Canada, which reduced operating loss. The sale generated $8.2 million in cash consideration before $0.4 million of transaction costs.
- Cash and cash equivalents increased by $49.5 million, supported by a July 2020 public offering that generated $71.3 million net proceeds and $5.7 million from option exercises. Operating cash use increased year over year.
Outlook, risks, and unusual items
- Management estimated existing cash would fund operating expenses and capital requirements into 2023, based on its current operating plan. It expects continued losses and anticipates needing additional capital; no revenue or profitability guidance was provided.
- The FDA placed NL-201’s IND on clinical hold in January 2021, requesting a more precise protein-dose assay and evidence that dosing procedures deliver the intended dose, plus other IND responses. Management said it was working to address the requests and expected to resolve the hold and begin enrollment in the first half of 2021, but stated there was no definitive timeline.
- NL-201 had not been tested in human clinical trials as of the report. Development, safety, regulatory approval, manufacturing, intellectual-property protection, competition, and financing are material risks. The company also cited possible COVID-19 disruptions to research, manufacturing, and planned trials.
- Preclinical work on NL-CVX1, a de novo SARS-CoV-2 decoy protein, showed in-vitro activity and protection in Syrian hamsters; the company was planning a first-in-human trial and said it would reassess the program as conditions evolved.
- The University of Washington license entails future maintenance fees, development and regulatory milestones, commercial milestones, low-single-digit royalties, and potential sublicense or transaction payments.
- The financial statements received an unmodified audit opinion. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Confirm the issuer: the supplied 10-K is for Neoleukin Therapeutics, not Neurogene Inc.
- Check subsequent FDA filings and announcements for the NL-201 clinical-hold resolution, trial authorization, and actual enrollment timing.
- Review the company’s current cash, burn rate, financing activity, and whether the stated runway into 2023 remains valid.
- Assess later clinical and safety data for NL-201 and progress or changes in the NL-CVX1 program.
- Verify the effects of equity issuance, pre-funded warrants, stock compensation, and outstanding options on dilution.
- Review the lease commitments, University of Washington license economics, and any changes to contingent payments or intellectual-property rights.